When assessing new techniques for use with marginalized populations, it is critical to consider costs and benefits free of unexamined biases. Anything less is discriminatory and unjust.
Because regulatory approval of cognitive enhancement drugs is likely, physicians may want to consider whether they would condone the practice for restoration of function only or for enhancement purposes as well.